MENU
+Compare
IDNA
ETF ticker: NYSE ARCA
AS OF
Apr 24, 01:17 PM (EDT)
Price
$20.46
Change
+$0.19 (+0.94%)
Net Assets
105.96M

IDNA stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM... Show more

Category: #Health
IDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for IDNA with price predictions
Apr 23, 2025

IDNA's RSI Indicator climbs out of oversold territory

The RSI Oscillator for IDNA moved out of oversold territory on April 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on IDNA as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IDNA just turned positive on April 16, 2025. Looking at past instances where IDNA's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

IDNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IDNA entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.

Market Cap

The average market capitalization across the iShares Genomics Immnlgy & Hlthcr ETF ETF is 18.29B. The market cap for tickers in the group ranges from 157.43M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is FDMT at 157.43M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was 35%. For the same ETF, the average monthly price growth was 22%, and the average quarterly price growth was 127%. ARCT experienced the highest price growth at 23%, while DNA experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was 15%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was -2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 78
Price Growth Rating: 69
SMR Rating: 80
Profit Risk Rating: 86
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
IDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com